Singular Genomics Systems Inc (NAS:OMIC)

$ 19.6 0.18 (0.93%) Market Cap: 49.66 Mil Enterprise Value: -14.14 Mil PE Ratio: 0 PB Ratio: 0.40 GF Score: 33/100

Q2 2024 Singular Genomics Systems Inc Earnings Call Transcript
Aug 13, 2024

$7.12

Earnings
Q1 2024 Singular Genomics Systems Inc Earnings Call Transcript
May 14, 2024

$12.89 (+0.37%)

Earnings
Q4 2023 Singular Genomics Systems Inc Earnings Call Transcript
Mar 18, 2024

$16.42 (+9.48%)

Earnings
Q3 2023 Singular Genomics Systems Inc Earnings Call Transcript
Nov 14, 2023

$11.07 (+5.40%)

Earnings
Singular Genomics Systems Inc at UBS Genomics 2.0 and MedTech Innovations Summit Transcript
Aug 16, 2023
Q2 2023 Singular Genomics Systems Inc Earnings Call Transcript
Aug 09, 2023

$21.03 (-3.97%)

Earnings
Singular Genomics Systems Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Q1 2023 Singular Genomics Systems Inc Earnings Call Transcript
May 09, 2023

$33 (+4.76%)

Earnings
Q4 2022 Singular Genomics Systems Inc Earnings Call Transcript
Mar 02, 2023

$62.7 (+6.63%)

Earnings
Singular Genomics Systems Inc at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Q3 2022 Singular Genomics Systems Inc Earnings Call Transcript
Nov 07, 2022

$67.2 (-2.61%)

Earnings
Singular Genomics Systems Inc at UBS Genomics 2.0 and MedTech Innovations Summit Transcript
Aug 11, 2022
Q2 2022 Singular Genomics Systems Inc Earnings Call Transcript
Aug 09, 2022

$133.5 (-3.68%)

Earnings
Singular Genomics Systems Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 14, 2022
Q1 2022 Singular Genomics Systems Inc Earnings Call Transcript
May 10, 2022

$101.4 (+2.42%)

Earnings
Q4 2021 Singular Genomics Systems Inc Earnings Call Transcript
Mar 02, 2022

$233.4 (-3.59%)

Earnings

Singular Genomics Systems Inc at UBS Genomics 2.0 and MedTech Innovations Summit Transcript

Aug 16, 2023 / 04:00PM GMT

Release Date Price: $15.77 (-1.87%)

Transcript 10-Q8-K

John Newton Sourbeer

UBS Investment Bank, Research Division - Equity Research Associate

Welcome to our next fireside chat. I'm John Sourbeer, one of the UBS Life Sciences analyst. Joining me on stage is my co-coverage, Alysa Garcia. We're happy to host Singular Genomics here for our next fireside chat. With us today on stage is Drew Spaventa, Founder and CEO; and Dalen Meeter, who's Head of Finance. Thanks for joining us.

Questions & Answers

John Newton Sourbeer

UBS Investment Bank, Research Division - Equity Research Associate

So maybe kick things off here. Let's start with the G4 launch. So you now have 11 commercial units in the field. Maybe you can provide some of the initial feedback from customers? Any learnings that you've now had over the last 3 quarters since the launch?

Andrew Spaventa

Singular Genomics Systems, Inc. - Founder, CEO, President & Chairperson of the Board

Yes, yes. And first of all, thanks for having us. It's good to be here. The G4 launch is underway at this point. Just to

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.